Clinical Trials in San Antonio

Showing 3161-3180 of 12,572 trials

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

NCT06240728

NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response. The goal of this first-in-human study is to learn whether NPX887 is safe and tolerable and shows a preliminary efficacy in participants with B7-H7 (HHLA2) expressing tumors at selected dose(s). The main questions it aims to answer are: * what is an appropriate dose to be given to participants? * are the side effects of treatment manageable? * what is the preliminary anti-tumor activities? Participants who are treated will receive an intravenous (IV) infusion of NPX887 if their disease has not progressed, and be closely monitored by the treating physicians.

Metastatic Malignant Neoplasm

NextPoint Therapeutics, Inc.144 participantsStarted Jan 2024

Baltimore, Maryland, United States • Boston, Massachusetts, United States • The Bronx, New York, United States +5 more locations

TERMINATEDPhase 1< 1 mile

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

NCT03786926

An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas

Lymphoma

Hutchmed53 participantsStarted Aug 2019

Anaheim, California, United States • Anaheim, California, United States • Oxnard, California, United States +24 more locations

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

Find Trials by Condition in San Antonio

A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Post-Approval Study of the TREO Abdominal Stent-Graft System

LTFU for All Cell and Gene Therapy Studies

Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel

Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome

Open Label Extension for 43USSA1812

BIG Study (Brain, Immune, and Gut Health Evaluation of Infants/Young Children Fed Infant Formula, and Later Supplemental Toddler Nutrition, With 5 Specific HMOs)

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

International Rare Histiocytic Disorders Registry (IRHDR)

The Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT)

A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Cough Reduction in IPF With Nalbuphine ER